You just read:

Biohaven Announces Successful Achievement of Both Co-Primary Regulatory Endpoints in Two Pivotal Phase 3 Trials of Rimegepant an Oral CGRP Receptor Antagonist for the Acute Treatment of Migraine

News provided by

Biohaven Pharmaceutical Holding Company Ltd.

Mar 26, 2018, 03:00 ET